Is Nyrada Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Nyrada Inc (NYR.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Nyrada Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nyrada Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Nyrada Inc?

Muslim investors may consider investing in Nyrada Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Nyrada Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Nyrada Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Nyrada Inc updated?

The Shariah compliance status of Nyrada Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Nyrada Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Nyrada Inc?

You can check the latest Shariah compliance status of Nyrada Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NYR.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 29, 2025

Report Source: 2025 2nd Quarter Report

Nyrada Inc. Stock Analysis NYR.AX

Australia Health Care Nano Cap Report: Q2, 2025

Nyrada, Inc. is a pre-clinical stage, drug discovery, and development company, which engages in the business of specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection. The NYR-BI03 has potential to fill a significant treatment gap targeting ischemia-reperfusion injury. NYR-BI03 additionally has the potential to provide dual protection for both the heart and brain from ischemia-reperfusion damage, helping prevent heart failure and neurological damage. Its Neuroprotection Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischaemic stroke. Its Cardioprotection Program is a cardioprotectant drug to reduce the damage to the heart following myocardial infarction (heart attack).

Key Statistics of Nyrada Inc (NYR.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.55AUD0.56

Today's Open

AUD0.55

Volume

155.25K

P/E Ratio (TTM)

52 Week Range

AUD0.11AUD1.44

Market Cap

33.65M

Avg. Volume

87.79K

Dividend Yield

Financial Metrics & Statements of Nyrada Inc (NYR.AX)

FAQ's for Nyrada Inc (NYR.AX)

According to Musaffa’s Shariah screening methodology, Nyrada Inc (NYR.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.